Product Information
INCRUSE ELLIPTA 62.5 MCG INH is a brand product labeled by GlaxoSmithKline LLC, priced at $11.2935 per EA under NDC 00173087310. Its NADAC has been published 588 times since May 20, 2015.
FDA first approved this application on Apr 30, 2014.
Strength
62.5 ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173087310
Classification
Brand
Dosage Form
AEROSOL, POWDER
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
UMECLIDINIUM BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA205382FDA Approved
4/30/2014
On Market Since
4/30/2014
Pharmacological Classes
Price Statistics
The NADAC for INCRUSE ELLIPTA 62.5 MCG INH has been published 588 times since May 20, 2015, and over the history we have for it it has risen 56.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.2935 per EA |
|---|---|
| All-time high | $11.3292 (Apr 10, 2024) |
| All-time low | $7.2002 (May 20, 2015) |
| 52-week high | $11.3106 |
| 52-week low | $11.2935 |
| Median price | $10.9859 |
| Average price | $10.6022 |
| Largest weekly change | +9.0% (Oct 12, 2016) |
| Weeks tracked | 588 |
| Tracking since | May 20, 2015 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 9% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of INCRUSE ELLIPTA 62.5 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for INCRUSE ELLIPTA 62.5 MCG INH, manufactured by GlaxoSmithKline LLC, is $11.2935 per EA (NDC 00173087310), effective Aug 19, 2026.
How has the price of INCRUSE ELLIPTA 62.5 MCG INH changed over time?
Over the history we have for it, the NADAC for INCRUSE ELLIPTA 62.5 MCG INH has risen 56.8%. It has been tracked across 588 weekly CMS publications since May 20, 2015.
What are the highest and lowest recorded NADAC prices for INCRUSE ELLIPTA 62.5 MCG INH?
Since May 20, 2015, the NADAC for INCRUSE ELLIPTA 62.5 MCG INH has ranged from a low of $7.2002 (May 20, 2015) to a high of $11.3292 (Apr 10, 2024), with a median of $10.9859 per EA.
Are there cheaper alternatives to INCRUSE ELLIPTA 62.5 MCG INH?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, INCRUSE ELLIPTA 62.5 MCG INH, is $10.2770 per EA — about 9% below INCRUSE ELLIPTA 62.5 MCG INH.
Who manufactures INCRUSE ELLIPTA 62.5 MCG INH?
INCRUSE ELLIPTA 62.5 MCG INH (NDC 00173087310) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.